Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy

Journal of the National Cancer Institute

Volumn 110, Issue 1, 2018, Pages 87-96

  Suciu, Stefan ^a   Eggermont, Alexander M M ^b   Lorigan, Paul ^c   Kirkwood, John M ^d   Markovic, Svetomir N ^e   Garbe, Claus ^f   Cameron, David ^g   Kotapati, Srividya ^h   Chen, Tai Tsang ^h   Wheatley, Keith ⁱ   Ives, Natalie ⁱ   De Schaetzen, Gaetan ^a   Efendi, Achmad ^j   Buyse, Marc ^k  

^a EORTC DATA CENTER   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e MAYO CLINIC ROCHESTER   (United States)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j BRAWIJAYA UNIVERSITY   (Indonesia)

^k INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; PLACEBO; QS 21; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RISK FACTOR; VACCINATION; ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; MELANOMA; META ANALYSIS; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN NEOPLASMS; SURVIVAL RATE; VALIDATION STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; MELANOMA; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 85030426167     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx133     Document Type: Article

References (53)

1. Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoints. New York: Springer; 2005.
2. Leo A Di, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003;21(10):2045-2047.
3. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101(23):1642-1649.
4. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Lancet. 2000;356(9227): 373-378.
5. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008; 26(12):1987-1992.
6. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with bio-chemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2, 621 patients J Clin Oncol. 2007;25(34):5426-5434.
7. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33): 5218-5224.
8. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials J Clin Oncol. 2008;26(4):527-534.
9. Flaherty KT, Hennig M, Lee SJ, et al. Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials. Lancet Oncol. 2014;15(3):297-304.
10. Halabi S, Vogelzang NJ, Ou S-S, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009;27(17):2766-2771.
11. Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T, Alonso A. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials. 2002;23(6):607-625.
12. Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat Med. 1997;16(17):1965-1982.
13. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1(1):49-67.
14. Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014; 383(9919):816-827.
15. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol. 2009;27(36):6199-6206.
16. Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2, 313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14): 2452-2459.
17. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17.
18. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5): 1670-1677.
19. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1-5mm without clinically detectable node metastases. Lancet. 1998;351(9120): 1905-1910.
20. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegy-lated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet. 2008; 372(9633):117-126.
21. Eggermont AMM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810-3818.
22. Wheatley K, Ives N, Eggermont A, et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. In: ASCO Annual Meeting; 2007; Chicago (IL), USA: Proceedings Part I. Vol. 25, No. 18S.
23. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N EnglJ Med. 2010;363(8):711-723.
24. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.
25. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5): 522-530.
26. Burzykowski T, Buyse M. Surrogate threshold effect: An alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat. 2006;5(3): 173-186.
27. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19): 1845-1855.
28. Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation ofsur-rogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C (Applied Stat). 2001;50(4):405-422.
29. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: Multivariate approach and meta-regression. Stat Med. 2002;21(4): 589-624.
30. Michiels S, Le Maître A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: Meta-analyses of individual patient data. Lancet Oncol. 2009;10(4):341-350.
31. Ng R, Pond GR, Tang PA, MacIntosh PW, Siu LL, Chen EX. Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol. 2008;19(3): 481-486.
32. Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Onco Targets Ther. 2012;5:287-296.
33. Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113(4): 1020-1034.
34. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444-2458.
35. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;13(11):2776-2783.
36. Eggermont AMM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet. 2005;366(9492):1189-1196.
37. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet. 2001;358(9285):866-869.
38. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: The AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22(1):53-61.
39. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19(6):1195-1201.
40. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer. 2001;84(9):1146-1149.
41. Kleeberg UR, Suciu S, Bröcker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. Eur J Cancer. 2004;40(3):390-402.
42. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9): 2370-2380.
43. Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001;19(5):1430-1436.
44. Payne MJ, Argyropoulou K, Lorigan P, et al. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol. 2013;32(3):185-190.
45. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16(4):1425.
46. Hansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): A randomised phase 3 trial. Lancet Oncol. 2011; 12(2):144-152.
47. Mao L, Si L, Chi Z, et al. A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients. Eur J Cancer. 2011;47(10):1498-1503.
48. McMasters KM Reintgen DS, et al. Final results of the Sunbelt Melanoma Trial. 2008;(26: suppl 9003).
49. Grob JJ, Jouary T, Dréno B, et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer. 2013;49(1):166-174.
50. Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009;27(6):939-944.
51. Hauschild A, Weichenthal M, Balda B-R, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21(15):2883-2888.
52. Hauschild A, Weichenthal M, Rass K, et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol. 2009;27(21):3496-3502.
53. Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60months of treatment in patients with primary melanoma of >= 1.5mm tumor thickness: Results of a randomized phase III DeCOG trial. J Clin Oncol. 2010;28(5):841-846.